Who are Levaquin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pradaxa, Protonix, Levaquin, Zofran, Pepcid, Zantac.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levofloxacin-in-dextrose-5-in-plastic-container.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Levaquin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Levaquin (Levofloxacin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone Antibacterial [EPC].

marketed Fluoroquinolone Antibacterial [EPC] Multidrug and toxin extrusion protein 1 Small molecule Live · refreshed every 30 min

Target snapshot

Levaquin (Levofloxacin) — Santen. Levaquin works by inhibiting bacterial DNA replication and transcription by binding to the enzyme DNA gyrase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levaquin TARGET	Levofloxacin	Santen	marketed	Fluoroquinolone Antibacterial [EPC]	Multidrug and toxin extrusion protein 1	1996-01-01
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	marketed	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Zofran	ondansetron	GSK (originally Glaxo)	marketed	5-HT3 receptor antagonist (antiemetic)	Aldehyde oxidase, 5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1	1991-01-04
Pepcid	famotidine	Generic (originally Yamanouchi/Merck)	marketed	Histamine-2 Receptor Antagonist [EPC]	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2	1986-10-01
Zantac	ranitidine	GSK (originally Glaxo)	marketed	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-11-23 — Zofran · 8580830 · Formulation · US
2030-07-13 — Zofran · 9095577 · Formulation · US

Sponsor landscape (Fluoroquinolone Antibacterial [EPC] class)

Generic (originally Daiichi Sankyo/J&J) · 1 drug in this class
Santen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levaquin — Competitive Intelligence Brief. https://druglandscape.com/ci/levofloxacin-in-dextrose-5-in-plastic-container. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab